Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency of cytotoxic drugs.  This type of targeted delivery can minimize harm to healthy tissues, reducing side effects and potentially improving the therapeutic window. However, the complex structure of ADCs poses significant development and safety challenges …Read More >

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have developed comprehensive discovery platforms capable of investigating the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation. Our broad and deep expertise spans diverse TPD modalities, including PROTACs®, molecular …Read More >

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer cell populations.  The ability of ADCs to deliver highly potent cytotoxic payloads directly to cancer cells that express a target antigen makes them a promising approach for targeted therapy.  However, the complex structure and mechanism …Read More >

Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs).  Our platform enables research teams to investigate the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation.  Our end-to-end services encompass over 20 assay technologies, 10+ types of TPD molecules, and one-stop screening …Read More >

Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across the world. Body Mass Index (BMI) is a commonly used indicator to assess the degree of obesity. According to the World Obesity Atlas 2025, by 2030, over 2.9 billion adults globally will have a high …Read More >

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where cytotoxic payloads released by antibodies diffuse and kill nearby tumor cells, is a crucial mechanism, particularly in heterogeneous tumors where not all cells express the target antigen. This effect can enhance ADC efficacy, especially when …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 Festival …Read More >

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the largest and longest-standing cancer research conferences in the world, will be held in Chicago. At this year’s AACR meeting, WuXi Biology has been selected to present several posters detailing latest scientific insights, covering a range …Read More >

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors to evade the immune system. IDO1 can also suppress the immune response through mechanisms independent of its enzyme activity, and this may be difficult to target with current inhibitors.  Drugs targeting only IDO1 enzyme activity …Read More >